A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy
Cadrin-Tourigny, Julia; Bosman, Laurens P.; Nozza, Anna; Wang, Weijia; Tadros, Rafik; Bhonsale, Aditya; Bourfiss, Mimount; Fortier, Annik; Lie, Øyvind H.; Saguner, Ardan M.; Svensson, Anneli; Andorin, Antoine; Tichnell, Crystal; Murray, Brittney; Zeppenfeld, Katja; Van Den Berg, Maarten P.; Asselbergs, Folkert W.; Wilde, Arthur A.M.; Krahn, Andrew D.; Talajic, Mario; Rivard, Lena; Chelko, Stephen; Zimmerman, Stefan L.; Kamel, Ihab R.; Crosson, Jane E.; Judge, Daniel P.; Yap, Sing Chien; Van Der Heijden, Jeroen F.; Tandri, Harikrishna; Jongbloed, Jan D.H.; Guertin, Marie Claude; Van Tintelen, J. Peter; Platonov, Pyotr G.; Duru, Firat; Haugaa, Kristina H.; Khairy, Paul; Hauer, Richard N.W.; Calkins, Hugh; Te Riele, Anneline S.J.M.; James, Cynthia A.
(2019) European Heart Journal, volume 40, issue 23, pp. 1850 - 1858
(Article)
Abstract
Aims Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVC) is characterized by ventricular arrhythmias (VAs) and sudden cardiac death (SCD). We aimed to develop a model for individualized prediction of incident VA/ SCD in ARVC patients. Methods Five hundred and twenty-eight patients with a definite diagnosis and no history of sustained VAs/SCD at
... read more
baseline, and results aged 38.2 ± 15.5 years, 44.7% male, were enrolled from five registries in North America and Europe. Over 4.83 (interquartile range 2.44–9.33) years of follow-up, 146 (27.7%) experienced sustained VA, defined as SCD, aborted SCD, sustained ventricular tachycardia, or appropriate implantable cardioverter-defibrillator (ICD) therapy. A prediction model estimating annual VA risk was developed using Cox regression with internal validation. Eight potential predictors were pre-specified: age, sex, cardiac syncope in the prior 6 months, non-sustained ventricular tachycardia, number of premature ventricular complexes in 24 h, number of leads with T-wave inversion, and right and left ventricular ejection fractions (LVEFs). All except LVEF were retained in the final model. The model accurately distinguished patients with and without events, with an optimism-corrected C-index of 0.77 [95% confidence interval (CI) 0.73–0.81] and minimal over-optimism [calibration slope of 0.93 (95% CI 0.92–0.95)]. By decision curve analysis, the clinical benefit of the model was superior to a current consensus-based ICD placement algorithm with a 20.6% reduction of ICD placements with the same proportion of protected patients (P < 0.001). Conclusion Using the largest cohort of patients with ARVC and no prior VA, a prediction model using readily available clinical parameters was devised to estimate VA risk and guide decisions regarding primary prevention ICDs (www.arvcrisk.com).
show less
Download/Full Text
Keywords: Arrhythmogenic right ventricular cardiomyopathy, Implantable cardioverter-defibrillators, Sudden cardiac death, Ventricular arrhythmias, Cardiology and Cardiovascular Medicine, Journal Article
ISSN: 0195-668X
Publisher: Oxford University Press
Note: Funding Information: Fondation Leducq’ [grant number 16 CVD 02] to H.C.; the Dutch Heart Foundation [grant numbers 2015T058 to A.S.J.M.t.R.; CVON2015-12 eDETECT, 2012-10 PREDICT, CVON PREDICT Young Talent Program to A.S.J.M.t.R.]; the Netherlands Organisation for Scientific Research [040.11.586 to CAJ]; the Netherlands Heart Institute [project 06901]; the Swiss National Science Foundation [320030_160327]; the UMC Utrecht 2017 Alexandre Suerman Stipend to M.B.; and the UMC Utrecht Fellowship Clinical Research Talent to A.S.J.M.t.R. This project has received support from the European Union’s Horizon 2020 research and innovation program under the ERA-NET Co-fund action no. 680969 (ERA-CVD DETECTIN-HF). The Johns Hopkins ARVD Program is supported by the Dr Francis P. Chiaramonte Private Foundation, the Leyla Erkan Family Fund for ARVD Research, the Dr Satish, Rupal, and Robin Shah ARVD Fund at Johns Hopkins, the Bogle Foundation, the Healing Hearts Foundation, the Campanella family, the Patrick J. Harrison Family, the Peter French Memorial Foundation, and the Wilmerding Endowments. The Zurich ARVC Program is supported by grants from the Georg und Bertha Schwyzer-Winiker Foundation, the Baugarten Foundation, and the Swiss Heart Foundation. The Johns Hopkins ARVD Program and the Zurich ARVC Program are also supported by a joint grant from the Leonie-Wild Foundation. Drs R.T. and M.T. are supported by the Marvin and Philippa Carsley Chair of Medicine. F.W.A. is supported by UCL Hospitals NIHR Biomedical Research Centre. Funding Information: This work was supported by the Canadian Heart Rhythm Society George Mines Traveling Fellowship to J.C.-T.; the Montreal Heart Institute Foundation ‘Bal du Coeur’ bursary to J.C.-T.; by a grant from the Publisher Copyright: © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.
(Peer reviewed)